HiberCell
MA - BostonBiotechnology
Focus: HiberCell is a Boston-based oncology biotech focused on tumor dormancy detection and treatment modalities. The company is early-stage with a diversified pipeline across multiple cancer indications.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About HiberCell
AI assessmentNot HiringNo open roles listed right now. Follow HiberCell to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Imprime PGG
Colorectal CancerClinical Trials (1)
NCT00912327Efficacy and Safety Study of Imprime PGG With Cetuximab in Subjects With Stage IV KRAS-Mutated Colorectal Cancer
N/AHelp build intelligence for HiberCell
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.